Boston Partners Lowers Position in Johnson & Johnson $JNJ

Boston Partners lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,698,781 shares of the company’s stock after selling 60,514 shares during the period. Boston Partners owned approximately 0.07% of Johnson & Johnson worth $259,744,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Richmond Investment Services LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $708,000. J.W. Cole Advisors Inc. lifted its stake in shares of Johnson & Johnson by 15.4% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 128,165 shares of the company’s stock valued at $19,577,000 after purchasing an additional 17,143 shares in the last quarter. North Star Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 4.2% during the 2nd quarter. North Star Asset Management Inc. now owns 27,616 shares of the company’s stock worth $4,218,000 after purchasing an additional 1,118 shares during the period. Southeast Asset Advisors LLC increased its position in Johnson & Johnson by 7.4% during the 2nd quarter. Southeast Asset Advisors LLC now owns 41,987 shares of the company’s stock worth $6,414,000 after purchasing an additional 2,883 shares in the last quarter. Finally, Columbia Bank lifted its position in Johnson & Johnson by 4.5% during the second quarter. Columbia Bank now owns 22,727 shares of the company’s stock valued at $3,541,000 after buying an additional 976 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 2.8%

NYSE:JNJ opened at $193.76 on Wednesday. The stock has a market cap of $466.83 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The business’s 50-day simple moving average is $184.79 and its 200 day simple moving average is $169.31.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. UBS Group increased their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Citigroup upped their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, Raymond James Financial boosted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.